Login to Your Account



Other News To Note


Friday, June 14, 2013
• Cornerstone Therapeutics Inc., of Cary, N.C., said it received on June 11 a Paragraph IV notice letter from Exela Pharma Sciences LLC, of Lenoir, N.C., advising the firm of Exela's filing of a supplemental new drug application for use of an injectable form of nicardipine hydrochloride in 9 percent sodium chloride, a generic version of Cornerstone's Cardene I.V. premixed injection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription